ASH 2022 Post Conference Perspectives: Innovations in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Carlos M. De Castro, MD, highlights the phase III Apply-PNH study presented at ASH 2022.

Dr De Castro provides an overview of IV versus oral therapies for patients with PNH.

Biosimilar products may be utilized as treatment options in PNH.

Dr De Castro explores considerations surrounding cost in treatment of PNH.

In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment.